The surfaceome company

Transforming cancer care by expanding the molecular target space

Our Mission

Our mission is to improve patient care by unleashing the full potential of targeted cancer therapies using our transformative cell surfaceome discovery technology.

Our Pipeline

Our initial discovery projects are on Small Cell Lung Cancer and microsatellite-stable Colorectal Cancer. Other tumor types are in development.

Learn more

Science & Technology

Our pioneering surfaceome mapping platform expands the drug target universe, boosting the creation of novel therapeutics.

Learn more

Our Team

A stellar team of individuals with diverse backgrounds from academia, biotech and pharma.

Learn more

News & Events

DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing 11 December 2025
DISCO Pharmaceuticals appoints Ajla Hrle as Chief Business Officer 23 December 2024
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing 16 January 2024